首页> 美国卫生研究院文献>Journal of Cellular and Molecular Medicine >A proteomics approach to identifying novel protein targets involved in erinacine A–mediated inhibition of colorectal cancer cells’ aggressiveness
【2h】

A proteomics approach to identifying novel protein targets involved in erinacine A–mediated inhibition of colorectal cancer cells’ aggressiveness

机译:蛋白质组学方法用于鉴定与Erinacine A介导的结直肠癌细胞侵袭性抑制有关的新型蛋白质靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Erinacine A, a major active component of a diterpenoid derivative isolated from Hericium erinaceus mycelium, has been demonstrated to exert anticancer effects. Herein, we present an investigation of the molecular mechanism of erinacine A induction associated with cancer cells’ aggressive status and death. A proteomic approach was used to purify and identify the differentially expressed proteins following erinacine A treatment and the mechanism of its action in apoptotic and the targets of erinacine A. Our results demonstrate that erinacine A treatment of HCT‐116 and DLD‐1 cells increased cell cytotoxicity and reactive oxygen species (ROS) production as well as decreased cell proliferation and invasiveness. Ten differentially displayed proteins were determined and validated in vitro and in vivo between the erinacine A‐treated and untreated groups. In addition, erinacine A time‐dependent induction of cell death and inhibitory invasiveness was associated with sustained phosphorylation of the PI3K/mTOR/p70S6K and ROCK1/LIMK2/Cofilin pathways. Furthermore, we demonstrated that erinacine A–induced HCT‐116 and DLD‐1 cells viability and anti‐invasion properties by up‐regulating the activation of PI3K/mTOR/p70S6K and production of ROS. Experiments involving specific inhibitors demonstrated that the differential expression of cofilin‐1 (COFL1) and profilin‐1 (PROF1) during erinacine A treatment could be involved in the mechanisms of HCT‐116 and DLD‐1 cells death and decreased aggressiveness, which occurred via style="fixed-case">ROCK1/ style="fixed-case">LIMK2/Cofilin expression, with activation of the style="fixed-case">PI3K/ style="fixed-case">mTOR/p70S6K signalling pathway. These findings elucidate the mechanism of erinacine A inhibiting the aggressive status of cells by activating style="fixed-case">PI3K/ style="fixed-case">mTOR/p70S6K downstream signalling and the novel protein targets style="fixed-case">COF1 and style="fixed-case">PROF1; this could be a good molecular strategy to limit the aggressiveness of style="fixed-case">CRC cells.
机译:从猴头菇菌丝体中分离出的二萜类衍生物的主要活性成分Erinacine A已被证明具有抗癌作用。在本文中,我们研究了与癌细胞的侵袭性状态和死亡相关的Erinacine A诱导的分子机制。蛋白质组学方法用于纯化和鉴定erinacine A处理后差异表达的蛋白质,以及其在凋亡和erinacine A靶标中的作用机理。我们的结果表明,erinacine A处理HCT-116和DLD-1细胞会增加细胞细胞毒性和活性氧(ROS)产生,以及细胞增殖和侵袭性降低。确定了十种差异展示的蛋白质,并在经芥酸碱A处理的组和未经处理的组之间进行了体内和体外验证。此外,erinacine A时间依赖性诱导的细胞死亡和抑制性侵袭与PI3K / mTOR / p70S6K和ROCK1 / LIMK2 / Cofilin途径的持续磷酸化有关。此外,我们通过上调PI3K / mTOR / p70S6K的激活和ROS的产生证明了erinacine A诱导的HCT-116和DLD-1细胞的生存能力和抗侵袭特性。涉及特定抑制剂的实验表明,在Erinacine A治疗期间cofilin-1(COFL1)和profilin-1(PROF1)的差异表达可能与HCT-116和DLD-1细胞死亡和侵略性降低的机制有关,这通过 style =“ fixed-case”> ROCK 1 / style =“ fixed-case”> LIMK 2 / Cofilin表达式,并激活了 style =“ fixed-case” > PI 3K / style =“ fixed-case”> mTOR / p70S6K信号通路。这些发现阐明了erinacine A通过激活 style =“ fixed-case”> PI 3K / style =“ fixed-case”> mTOR / p70S6K抑制细胞侵袭性状态的机制。下游信号传导和新型蛋白靶向 style =“ fixed-case”> COF 1和 style =“ fixed-case”> PROF 1;这可能是限制 style =“ fixed-case”> CRC 细胞侵袭性的良好分子策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号